World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
34449
World Ranking
13490
National Ranking
1254

Paresh Vyas publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Paresh Vyas sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 535 publications — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Paresh Vyas D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Paresh Vyas sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Paresh Vyas is affiliated with the University of Oxford in the United Kingdom. Their research primarily addresses topics in medicine and biochemistry, genetics, and molecular biology, with a significant focus on hematology, molecular biology, and genetics as subfields.

Their work concentrates on multiple areas within hematologic malignancies and related treatments. Key research topics include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Protein Degradation and Inhibitors
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Multiple Myeloma Research and Treatments
  • Histone Deacetylase Inhibitors Research
  • Chronic Lymphocytic Leukemia Research

Paresh Vyas has contributed extensively to peer-reviewed journals. Frequent publication venues include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • HemaSphere

Notable recent papers authored by or involving Paresh Vyas are:

  • "International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data," published in Blood in 2022
  • "Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes," published in New England Journal of Medicine in 2020
  • "SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS," published in Blood in 2020
  • "Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial," published in The Lancet Oncology in 2021
  • "Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia," published in Journal of Clinical Oncology in 2020

Paresh Vyas has collaborated frequently with several researchers, including:

  • David A. Sallman
  • Naval Daver
  • Marlen Metzner
  • Andrew H. Wei
  • Courtney D. DiNardo

Best Publications

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Clinical and biological implications of driver mutations in myelodysplastic syndromes.

    Elli Papaemmanuil;Moritz Gerstung;Luca Malcovati;Sudhir Tauro

  • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

    Eytan M. Stein;Eytan M. Stein;Courtney D. DiNardo;Daniel A. Pollyea;Amir T. Fathi

  • Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts

    E. Papaemmanuil;M. Cazzola;J. Boultwood;L. Malcovati

  • Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

    Gerrit J. Schuurhuis;Michael Heuser;Sylvie Freeman;Marie Christine Béne

  • Assessment of Minimal Residual Disease in Standard-Risk AML.

    Adam Ivey;Robert Kerrin Hills;Michael A. Simpson;Jelena V. Jovanovic

  • Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.

    Max Jan;Thomas M. Snyder;M. Ryan Corces-Zimmerman;Paresh Vyas

  • Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia

    Nicolas Goardon;Emanuele Marchi;Ann Atzberger;Lynn Quek

  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

    Pierre Fenaux;Pierre Fenaux;Uwe Platzbecker;Ghulam J. Mufti;Guillermo Garcia-Manero

  • Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

    Oliver Goodyear;Angelo Agathanggelou;Igor Novitzky-Basso;Shamyla Siddique

  • Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

    Oliver C. Goodyear;Mike Dennis;Nadira Y. Jilani;Nadira Y. Jilani;Justin Loke

  • Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer

    Y S Ju;L B Alexandrov;M Gerstung;I Martincorena

  • Factors influencing success of clinical genome sequencing across a broad spectrum of disorders

    Jenny C. Taylor;Jenny C. Taylor;Hilary C. Martin;Stefano Lise;John Broxholme

  • Consequences of GATA-1 Deficiency in Megakaryocytes and Platelets

    Paresh Vyas;Kenneth Ault;Carl W. Jackson;Stuart H. Orkin

  • Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

    Alice Giustacchini;Supat Thongjuea;Nikolaos Barkas;Petter S Woll

  • THE MODE OF ACTION OF ASPIRIN-LIKE DRUGS : EFFECT ON INDUCIBLE NITRIC OXIDE SYNTHASE

    A R Amin;P Vyas;M Attur;J Leszczynska-Piziak

  • Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo

    Petter S. Woll;Una Kjällquist;Onima Chowdhury;Helen Doolittle

  • Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

    Michael D. Amatangelo;Lynn Quek;Alan Shih;Eytan M. Stein

  • The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: evidence for up-regulated neuronal nitric oxide synthase.

    A. R. Amin;P. E. Di Cesare;Pranav Vyas;Mukundan Attur

  • Results of the phase i trial of RG7112, a small-molecule MDM2 antagonist in leukemia

    Michael Andreeff;Kevin R. Kelly;Karen Yee;Sarit Assouline

Frequent Co-Authors

Charles Craddock
Charles Craddock Queen Elizabeth Hospital Birmingham
Irene Roberts
Irene Roberts University of Oxford
Peter J. Campbell
Peter J. Campbell Wellcome Sanger Institute
Nigel H. Russell
Nigel H. Russell University of Nottingham
Eva Hellström-Lindberg
Eva Hellström-Lindberg Karolinska University Hospital
Mario Cazzola
Mario Cazzola University of Pavia
David Grimwade
David Grimwade King's College London
Anna Schuh
Anna Schuh University of Oxford
Robert Kerrin Hills
Robert Kerrin Hills University of Oxford
Douglas R. Higgs
Douglas R. Higgs University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always require going to medical school. There are a variety of healthcare administration degree options available online. These programs are ideal for those who want to focus on the business side of healthcare, such as managing hospitals or leading healthcare teams.

For nurses seeking to advance their careers, rn to fnp bridge programs offer a flexible way to transition from an Associate Degree in Nursing (ADN) to becoming a Family Nurse Practitioner (FNP). These online pathways allow working professionals to upskill while still supporting patient care.

Nutrition is another crucial field in healthcare. If you’re interested in dietetics or wellness coaching, an online nutritionist degree can open doors to roles in hospitals, clinics, and community organizations.

As you compare programs, accreditation is vital. Learn more about which online healthcare administration programs have cahme accreditation? to ensure your degree meets industry standards and enhances your career prospects.

Best Scientists Citing Paresh Vyas

Trending Scientists